At the Library

Research Articles

peer reviewed on GcMAF
(primarily cancer)

GcMAF is Essential for Survival!

"Some biological properties of a partially deglycosylated (basically deactivated) DBP (vitamin D binding protein or Gc protein), called DBP-MAF (GcMAF) are however very exciting because of its very potent antiviral and antitumoral activity."

"... Vitamin D Binding protein (DBP or typically called Gc protein) may be essential for normal development and survival."  ~
ScienceDirect (peer-reviewed journal)

NOTE: Vitamin D is responsible for activating Gc protein which in turn activates the macrophages. The macrophages are the front line defense against all pathogens and initiate an immune response to all invaders. Without macrophages we do not have an Immune System. Therefore, our very survival is in the "hands" of the macrophages.

Disease Occurs Because a Lack of Gc Protein

Gc proteins circulate in many organs and the plasma. These proteins when activated by vitamin D3 in turn activate macrophages. These cells activate the immune system and seek out and destroy all invading cells which are not identified as normal healthy cells including... all types of pathogens, viruses, bacteria, fungi, and even cancer cells. In fact, it is reported... "Liver diseases, nephrotic syndrome, malnutrition, septic shock, or trauma is characterized by low plasma DBP concentrations (vitamin D Binding protein or often called Gc proteins), due to a diminished synthesis rate or an excessive protein loss/ consumption." ​~ScienceDirect (peer-reviewed journal)

NOTE: As you read through these amazing research articles please keep in mind... Cancer cells secrete an enzyme called Nagalase. Nagalase is known to deactivate the macrophages. This takes your immune system out of the healing process. Without the macrophages you will never win a battle against any disease.

When you see the levels of Nagalse expressed, please note that numbers LOWER than 0.92 nmole/min/mg protein are normal readings. The LOWER the Nagalase the LOWER the cancer burden. The HIGHER the Nagalase the HIGHER the cancer burden.

Amazing Results on Many Types of Disease

​Vitamin D binding protein (also known as D Binding Protein and Gc protein) acquires the ability to activate macrophages; this form is referred to as Gc-MAF (Macrophage Activating Factor)

Vitamin D binding protein (Gc protein) has been proven to affect host susceptibility to many diseases, including (but not limited to)... chronic obstructive pulmonary disease (COPD), endometriosis, osteoporosis, autism, systemic lupus erythematosus (SLE) and multiple types of cancer such as melanoma, squamous cell carcinoma and oral cancer.

In most cases GcMAF was basically deactivated by an enzyme called α-N-acetylgalactosaminidase (nagalase)."

"Previous studies have shown increased plasma levels of Nagalase in many types of cancer (all cancers) . . . Further studies showed a correlation between increased nagalase and the pathogenesis (biological mechanism(s) that leads to a diseased state) of cancer cells..."

"Today the strategy of many promising cancer therapies are to increase Gc-MAF levels and in doing so, hoping to reduce plasma nagalase." ~
JBUON (peer-reviewed Journal)

Amazing Results on Many Types of Cancer

​"GcMAF has some interesting biological activities, such as Promotion of Macrophage Activation via superoxide generation, and phagocytic activation (activation that engulfs and destroys pathogens), in addition to antiangiogenic (inhibits growth of new blood vessels for tumors) and antitumor activities. GcMAF has also been shown to have clinical activity against metastatic colorectal, metastatic breast, and prostate cancer, with additional activities in non-anemic HIV-infected patients."

Vitamin D Plays a Crucial Protective Role in Cancer

​"The so-called vitamin D axis is involved in various aspects of human breast cancer, the most common human tumor. The vitamin D axis is composed of the biologically active form of vitamin D3, and by two proteins that specifically bind it. These proteins are the vitamin D receptor (VDR) and the vitamin D binding protein that is the precursor of the vitamin D binding protein-derived Macrophage Activating Factor, also termed GcMAF. The role of vitamin D in human breast cancer is witnessed by the number of studies that have been published on the subject"

"Many studies have examined the effects of vitamin D on mammary carcinogenesis in vitro and in animal models, and the data support a protective role for vitamin D in breast cancer development."

NOTE: Vitamin D is responsible for activating Gc protein which in turn activates the macrophages. This is why Vitamin D plays such a CRUCIAL role in our health. Without macrophages we do not have an Immune System.

Breast Cancer

GcMAF, probably one of the MOST POTENT MACROPHAGE ACTIVATORS so far discovered, GcMAF-activated Macrophages induce human BREAST CANCER cell apoptosis (cell death) and the subsequent reduction of the cancer cell mass following phagocytosis (cell devouring process) of apoptotic (dead) cancer cells by macrophages.”

​"In this study we demonstrate that GcMAF stimulates Macrophages, which in turn attack human BREAST CANCER, induce their apoptosis (cell death) and eventually phagocytize (engulf and destroy) them." ~

Female, born 1947Cancer of Left Breast (found on survey), operated with sentinel nodes in 2010, chemotherapy 4 of 6 series, no specific complaints left. Still some malaise, fatigue and sleep-disorder. GcMAF-treatment (predominantly intravenous route). Aspecific complaints diminished.

  • Nagalase level at presentation on August 9, 2011: (1.70)

  • January 16, 2012: (1.00)

  • March 12, 2012: (0.72)

  • GcMAF discontinued in April 2012

  • December 11, 2012: (0.60)​

According to the literature, the normalization of serum nagalase activity in breast carcinoma patients may represent an index of TUMOR ERADICATION.

NOTE: Within 5 months the serum Nagalase activity dropped to nearly normal levels (< 0.92). And at 7 months it was below the high range of normal. What is most promising is that even when the GcMAF was discontinued (in April) the Nagalase levels continued to drop. This indicates that at some point the GcMAF is so powerful at activating Macrophages that they continue to rebuild like in a normal healthy body." ~ ​​

Female, born 1950Cancer of Left Breast 

specific complaints, metastases probable. After local operation, irradiation of thorax, combined with chemotherapy, Herceptin-therapy. Partly complaints in association with treatments. 

Nagalase levels...

  • at presentation on May 11, 2011: (5.60)

  • October 6, 2011: (2.90)

  • February 21, 2012: (1.80) ​

  • October 18, 2012: (1.10) 

"Treated with intramuscular, later intravenous GcMAF, and a few acupuncture-treatments. No further complaints (subsided in 3–6 weeks), still in intravenous GcMAF regimen. A significant decrease in serum nagalase activity could be observed approximately 5 mo after the initiation of therapy. Approximately after 17 mo of GcMAF treatment, serum nagalase levels approached normal values." 

Metastatic Breast Cancer (16 patients)

"Serum vitamin D3-binding protein (Gc protein) is the precursor for the principal Macrophage Activating Factor (MAF). The MAF precursor activity of serum Gc protein of breast cancer patients was lost or reduced because Gc protein was deglycosylated (basically deactivated) by serum alpha-N-acetylgalactosaminidase (Nagalase) secreted from cancerous cells."

​"Patient serum Nagalase activity is proportional to tumor burden. The deglycosylated Gc protein cannot be converted to MAF, resulting in NO Macrophage ACTIVATION and IMMUNOSUPPRESSION). 

Stepwise incubation of purified Gc protein with immobilized beta-galactosidase and sialidase generated probably the most potent Macrophage Activating Factor (termed GcMAF) ever discovered, which produces no adverse effect in humans."

"Macrophages treated in vitro with GcMAF (100 pg/ml) are highly tumoricidal to mammary adenocarcinomas."

"Efficacy of GcMAF for treatment of metastatic breast cancer was investigated with 16 nonanemic patients who received weekly administration of GcMAF (100 ng)."

"As GcMAF therapy progresses, the MAF precursor activity of patient Gc protein increased with a concomitant decrease in serum Nagalase. Because of proportionality of serum Nagalase activity to tumor burden, the time course progress of GcMAF therapy was assessed by serum Nagalase activity as a prognostic index." NOTE: When the Nagalase marker goes down this indicates the presence of MORE Macrophages AND LESS cancer."


  • "These patients had the initial Nagalase activities ranging from 2.32 to 6.28 nmole/min/mg protein."

  • "After about 16-22 administrations (approximately 3.5-5 months) of GcMAF, these patients had insignificantly low serum enzyme levels equivalent to healthy control enzyme levels, ranging from 0.38 to 0.63 nmole/min/mg protein, indicating eradication of the tumors."

​This therapeutic procedure resulted in no recurrence for more than 4 years."

​​Female, age 66. Lymphoma Cancer

Nagalase levels...

  • at first testing in August 2012: (2.20)

  • In November 2012: (1.90)

Improved. In this case, a clinical improvement was associated with a significant decrease in serum nagalase activity in about 3 mo after the initiation of GcMAF treatment." 

Female, age 58. Squamous Cell Carcinoma of the head and neck
Nagalase levels... 

  • First testing in June 2012: (2.90)

  • In July 2012: (2.70).

  • In February 2013: (2.00)

Improved. In this case, a minimal decrease in serum nagalase activity as observed after 1 mo of GcMAF administration was associated with clinical benefits." 

Female, age 35. Squamous Cell Cancer

  • Nagalase level at first testing in June 2012: (1.50)

  • In September 2012: (1.10). Discontinued

In this case, a decrease of serum nagalase activity was observed after 3 mo of GcMAF therapy. We are not aware of the reasons that led to treatment discontinuation." 

Male, age 63. Cancer of the Tongue (squamous cell)

Nagalase levels...

  • at first testing in July 2012: 3.00.

  • In September 2012: 1.50.

  • In December 2012: 1.00. Improved. 

​Again, clinical improvement was associated with a significant decrease in serum nagalase activity, which approached the normal range in approximately 5 mo. 

To the best of our knowledge, this is the first case of a patient affected by squamous cell carcinoma of the tongue receiving GcMAF. Also, another patient was treated with GcMAF for a squamous cell carcinoma of the tongue and showed a decrease in serum nagalase activity in about 3 mo." ​​

Thyroid Cancer

A 65 year old female patient with known thyroid cancer and complete standard treatment for 2 years. On the follow‑up visit, the patient revealed persistent increased CA 19‑9 (40.3 U/mL) and the thyroid function is as the following: Free triiodothyronine (FT3) = 2.53 pg/mL, free thyroxine (FT4) = 1.01 ng/dL, and thyroid stimulating hormone (TSH) = 1.44 µU/mL.

This case received GcMAF, extracted from peptide from human vitamin D receptor protein, at dosage 2,200 ng/0.5 ml intramuscularly weekly for continuous 5 weeks. After complete administration, the reduction of CA 19‑9 to 26.42 U/mL could be seen. 

This might imply that GcMAF might be useful for suppression of tumor marker increasing in the patient with thyroid cancer and complete standard treatment. ​

NOTE: The ca-19-9 normal range is any value that falls below 35 units per milliliter of blood. Generally speaking, if the ca-19-9 results are below 25 units per liter of ca-19-9 the person is considered to be healthy. 

Results of CA-19 Testing...

  • Your levels of CA 19-9 are increasing. This may mean your tumor is growing, and/or your treatment is not working.

  • Your levels of CA 19-9 are decreasing. This may mean your tumor is shrinking and your treatment is working.

  • Your levels of CA 19-9 have not increased or decreased. This may mean your disease is stable.

  • Your CA 19-9 levels decreased, but then later increased. This may mean your cancer has come back after you've been treated.

Male, born 1941Larynx Cancer spreads to Bladder

Lanyx Cancer was found and treated with curettage and irradiation in 2010. Hemorrhagic-rectocolitis in anamnesis, few complaints after 2005. 

Bladder carcinoma found in 2011, treated by local curettage and several cycles of BCG-instillations.

Complaints related to tumor growth and treatments, no chemotherapy.

​Treatment consisted of acupuncture and GcMAF intramuscular, and later intravenous injections weekly.

Nagalase levels...

  • At presentation on May 16, 2011: (4.70)

  • October 4, 2011: (2.00)

  • February 10, 2012: (1.20)

  • June 15, 2012: (1.00)

  • October 23, 2012: (0.88)

  • December 20, 2012: (0.90)

During the immunotherapy with GcMAF there were interesting developments. Insisting on bladder extirpation by the urologists, coped with one change of urologist, two second opinions by a specialized cancer clinic and later by an urologist of the operation team scheduled.

From the patients side there were several favorable adjustments in lifestyle, like discontinuation of smoking and adopting a daily intake of cod-liver-oil and salvia-leaf (his own initiative).

In the face of the urologists opinion I decided to give the GcMAF twice weekly over a period of six weeks.

The last opinion of the treating urologist was to postpone a more final decision to February, due to a much better impression of the bladder mucosa beginning in January 2013. There is optimism in the three named actors in the current situation. In this case, a significant decrease of in serum nagalase activation following the administration of GcMAF was associated with significant clinical benefits, consistent with previous reports." 


Metastatic Colorectal Cancer   

Serum vitamin D binding protein (Gc protein) is the precursor for the principal macrophage-activating factor (MAF). The MAF precursor activity of serum Gc protein (of colorectal cancer patients) was lost or reduced because Gc protein is [inactivated] by Nagalase which is secreted from cancerous cells. Inactivated Gc protein cannot be converted to MAF, leading to immunosuppression. Stepwise treatment of purified Gc protein with immobilized beta-galactosidase and sialidase generated the most potent macrophage-activating factor (GcMAF) ever discovered, but it produces no side effect in humans.

Female, age 60Ovarian Cancer

Nagalase levels...


  • at first testing in June 2012: (3.30)

  • November 2012: (2.80)

​The weekly administration of GcMAF resulted in a significant decrease of serum nagalase activity in about 3 mo. Such a decrease was associated with clinical benefits." ​ 

Macrophages treated with GcMAF (100 microg/ml) develop an enormous variation of receptors and are highly tumoricidal to a variety of cancers indiscriminately. Administration of GcMAF (100 nanogram (ng)/ human maximally) activates systemic macrophages that can kill cancerous cells. Since the half-life of the activated macrophages is approximately 6 days, 100 ng GcMAF was administered weekly to eight nonanemic colorectal cancer patients who had previously received tumor-resection but still carried significant amounts of metastatic tumor cells. As GcMAF therapy progressed, the MAF precursor activities of all patients increased and conversely their serum Nagalase activities decreased. Since serum Nagalase is proportional to tumor burden, serum Nagalase activity was used as a prognostic index for time course analysis of GcMAF therapy. 

NOTE: As GcMAF is INCREASED in the body the levels of Nagalase are LOWERED. The LOWER the nagalase the LESS cancer.

​"After 32-50 weekly administrations of 100 ng GcMAF, ALL COLORECTAL CANCER patients exhibited healthy control levels of the serum Nagalase activity, indicating ERADICATION of METASTATIC TUMOR CELLS."

During 7 years after the completion of GcMAF therapy, their serum Nagalase activity did not increase, indicating NO RECURRENCE of CANCER, which was also supported by the annual CT scans of these patients."

Male, age 54Colorectal Cancer

Nagalase levels...

  • at first testing in July 2012: 3.90

  • In October 2012: 2.00. Discontinued. 

In this case, a significant decrease of serum nagalase activity could be documented approximately 3 mo after the initiation of GcMAF therapy. We are not aware of the reasons that led to treatment discontinuation." 

Prostate - 16 Patients  

Serum Gc protein is the precursor for the principal Macrophage Activating Factor (MAF). The MAF precursor activity of serum Gc protein of prostate cancer patients was lost or reduced because Gc protein was made dysfunctional by Nagalase which is secreted from cancerous cells. Therefore, macrophages of prostate cancer patients having dysfunctional Gc protein cannot be activated, leading to immunosuppression

Macrophages activated by GcMAF develop a considerable variation of receptors that recognize the abnormality in malignant cell surface and are HIGHLY TUMORICIDAL. 

"Time course analyses of serum Nagalase activity of the prostate cancer patients assess the efficacy of GcMAF. These patients had the initial Nagalase activities ranging from 1.95 to 5.34 nmol/min per milligram (laboratory reference range for serum nagalase activity (0.90–0.92 nM/min/mg). As shown in Figure 3, the serum Nagalase activities of all 16 patients decreased as GcMAF therapy progressed."

"After approximately 14 to 25 administrations (14–25 weeks) of 100 ng of GcMAF, all 16 patients had very low serum Nagalase activity levels equivalent to those of healthy control values ranging from 0.37 to 0.68 nmol/min per milligram. These low enzyme activities are those of α-galactosidase and not of malignant specific Nagalase. Because serum Nagalase activity is proportional to tumor burden, the results suggest that these patients are FREE of CANCEROUS CELLS."

"During 7 years of observation after completion of GcMAF therapy, these patients showed no increase in their serum Nagalase activities, indicating NO RECURRENCE of prostate cancer."

"Furthermore, annual computed tomographic scans of these patients confirmed them being tumor recurrence–free for the 7 years."

Info on same article: "Prostatic cancer diagnosis and prognosis have been aided by the availability of PSA measurement. When patients received radical prostatectomy, a sudden drop of high PSA levels to very low values was observed. Thus, PSA is predominantly produced from primary tumor lesions in prostate compared with the metastasized lesions. Although serum Nagalase decreased during GcMAF therapy of patients with tumor bearing prostate, PSA remained unchanged. Therefore, PSA values cannot be used for prognostic assays during GcMAF therapy." Indexed on the full article here ​[PDF]

Male, born 1937. Prostate Cancer  

Found by PSA in 2009, no specific complaints.

Treated by hormone-injections, which gave complaints.

Before and in the same year colon carcinoma was found, and operated after irradiation and chemotherapy (no untreated tumor/ metastases probable).

Nagalase levels...

  • at presentation on April 6, 2011: (2.00)

  • August 29, 2011: (1.20)

  • January 5, 2012: (0.81)

  • July 5, 2012: (0.67)

  • December 6, 2012: (0.75)

Treatment with acupuncture and GcMAF; after some time, the hormone treatment was discontinued and complaints, also non-specific, improved a lot. Stays on low-frequency surveillance. Again, serum nagalase activity returned to normal values (0.75 nM/min/mg) after about 20 months of GcMAF treatment. A decrease in nagalase activity, however, was evident already at the first test, i.e., 4 mo after the initiation of GcMAF treatment. According to the literature, the normalization of serum nagalase levels in prostate cancer patients may represent an index of tumor eradication." 

4. Male, born 1948. Prostate Cancer

​in 2008; prostate extirpated in 2009 with good prognosis. However aspecific reports fatigue and pain stayed. GcMAF treatment was started, together with a few acupuncture treatments. Nagalase levels...

  • at presentation on October 21, 2011: (1.90)

  • February 2, 2012: (1.70)

  • October 19, 2012: (1.20)

  • Complaints decreased gradually and the injections were performed intravenously later on. The treatment continues." 

Male, age 67 Prostate Cancer
Nagalase levels...

  • at first testing in August 2012: (3.40) 

  • In December 2012: (2.80). Improved. 

In this case, clinical benefits were associated with a significant decrease in serum nagalase activity in about 4 mo from the initiation of GcMAF therapy. These results are consistent with the findings reported above as well as with previously described cases." 

1. Male, born 1950 Bladder Cancer

Since 2009, previously treated with chemo-solutions locally.

Nagalase levels...

  • at presentation on July 4, 2011: (3.10)

  • February 10, 2012: (2.30)

  • May 25, 2012: (1.80)

  • October 26, 2012: (1.40)

Treatment with GcMAF and acupuncture, later GcMAF only (later intravenous route).

Bladder considered clean by urologist in summer 2012. GcMAF-treatment continued. In this case, the consistent decrease in serum nagalase activity was associated with a significant clinical improvement. The drop in nagalase activity was evident at the first post-treatment testing, about 7 mo after the initiation of GcMAF treatment, and persisted until the last available determination, i.e., about 15 months thereafter. The difference in serum nagalase activity as recorded before at last determination and before the initiation of GcMAF therapy was (-1.70) nM/min/mg." 

​Female, born 1944.  Bladder Cancer

​Treated since 2011 by urologist with curettage and BCG.
Nagalase level...

  • at presentation on May 9, 2011: (4.10)

  • October 24, 2011: (2.30)

  • April 3, 2012: (1.40)

  • September 10, 2012: (1.00)

  • December 4, 2012: (0.75)

During the nagalase testing period the Patient was advised to inject intramuscular GcMAF weekly, but the Patient was not consistent. The bladder was considered in good condition on several occasions this period by the treating urologist. 

​Also in this case, a consistent decrease in serum nagalase activity was associated with a significant clinical improvement. Such a decrease in nagalase activity was evident at the first post-treatment testing, about 5 mo after the initiation of GcMAF treatment, and persisted until the last available determination, i.e., about 19 mo thereafter. The difference in serum nagalase activity as recorded before at last determination and before the initiation of GcMAF therapy was -3.35 nM/min/mg. The last available value of serum nagalase activity, 0.75 nM/min/mg, was within the normal range."

1. Male, age 64. Bladder Cancer

Nagalase levels...

  • at first testing in October 2012: (2.90) 

  • In January 2013: (2.60). Improved. 

In this case, a decrease in serum nagalase activity could be documented in about 3 mo of GcMAF treatment and was associated with clinical improvement. 

HIV Infected Patients 

Macrophages activated by administration of 100 ng GcMAF develop a large amount of Fc-receptors as well as an enormous variation of receptors that recognize IgG-bound and unbound HIV virions. Since latently HIV-infected cells are unstable and constantly release HIV virions, the activated macrophages rapidly intercept the released HIV virions to prevent reinfection resulting in exhaustion of infected cells.

After less than 18 weekly administrations of 100 ng GcMAF for nonanemic patients, they exhibited low serum Nagalase activities equivalent to healthy controls, indicating eradication of HIV-infection, which was also confirmed by no infectious center formation by provirus inducing agent-treated patient PBMCs. No recurrence occurred and their healthy CD + cell counts were maintained for 7 years.

What is CFS?

Chronic fatigue syndrome or myalgic encephalomyelitis (CFS/ME) is a devastating and complex disorder with uncertain cause.

People with CFS have overwhelming fatigue and a number of other symptoms that do not improve by bed rest and tend to get worse after physical activity or mental exertion.

They often function at a much lower level of activity than they were capable of before they became ill.

The primary symptoms of CFS is unexplained severe fatigue lasting at least 6 months that is not improved by bed rest. ​

​Defining symptoms of CFS include post-exertion malaise lasting more than 24 hours, unrefreshing sleep, impaired memory or concentration, muscle pain, pain in the joints without swelling or redness, headaches, tender lymph nodes in the neck or armpit and a sore throat that is frequent or recurring.

Many CFS patients may also experience other symptoms, such as irritable bowel syndrome, depression or other psychological problems, chills and night sweats, visual disturbances, brain fog, dizziness, problems with balance and sensitivities to foods, odors, chemicals, medications or noise.

Because there are no blood tests, scans or other laboratory tests to diagnose CFS, diagnosis is usually made by ruling out other possible diseases. As there are no prescription drugs developed specifically for CFS, it is generally considered as an incurable diseaseDoctors treating CFS tend to treat each of the symptoms individually with a wide range of drugs without much success.

The cause of CFS has as yet not been identified; however, infections and immune dysfunction are thought to play a critical role in the development of the disease. In addition, numerous viruses, such as Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6), HHV-7 and HHV-8, herpes simplex virus type 1 (HSV-1), HSV-2, measles virus, adenovirus type 2, Enterovirus and human cytomegalovirus (HCMV), have been implicated in subsets of patients.


A 71 year old female with CFS and suffering from symptoms, such as dizziness, chronic fatigue, palpitation, tachycardia, depression, unrefreshing sleep, stomach pain, regular sore throats and other disturbances for around 40 years.

​She was diagnosed, by physicians and psychotherapists, with autonomic neuropathy, climacteric disorder, depressive state, Meniere's disease, chronic gastritis, cardiac neurosis, chronic cystitis, post hepatitis B infection and colon polyps. Her blood tests showed no abnormality except cholesterol, which was slightly elevated, with sometimes borderline elevated transaminase levels. 

Brain magnetic resonance imaging (MRI) scan, cardiac catheter examination and gastroscopy showed no abnormality within the last 2 years. Colonoscopy showed colon polyps, which were removed during the colonoscopy examination and an abdominal computed tomography (CT) scan showed only a liver cyst.

On November 5th, 2014, she started taking daily colostrum MAF powder in the mouth, exposing the lymphoid tissue with the resident macrophages and, also, colostrum MAF orally in an acid-resistant enteric coated capsule. Within a few days, she noticed that her malaise, dizziness, tachycardia, insomnia, nocturnal urination and stomach pain were improving and she was feeling better with improved quality of life.

Over an one-month period, she also noticed that her skin became smooth and silky and that the blotches on her face and arms became lighter, disappearing in some places on the skin. She was very happy, being able to do her usual work with more energy like most other people do. Over a four-month period, she also noticed improvements in hair growth on her head. ~International Journal of Cancer Research and Treatment (peer-reviewed journal)


This last report concerns a 45-year-old female with CFS. She is the daughter of the previous case report patient. She had stomach pain, severe fatigue, especially after work, unrefreshing sleep, headaches, pain in the joints and other disturbances since she was 20 years old. When she was younger, her body weight was 43 kg, which declined over the years to 37-38 kg.

​Her fatigue could not improve by bed rest or taking medications and became worse with work. Her blood tests showed no abnormality and a brain MRI scan, abdominal MRI scan and an ultrasound scan were also normal. 

Gastroscopy showed gastritis and the presence of H. pylori bacteria in her stomach for which she was treated with antibiotics. After getting rid of the bacteria, her severe stomach pain continued and she was not able to control the symptoms even with proton pump inhibitors (PPIs).

On November 12th, she started taking colostrum MAF powder in the mouth and one capsule orally/day, as described in the previous case report. In a couple of days, she felt much better with reduced malaise in the morning and reduced stomach pain. She was able to move her body easily without the usual joint pain, muscle pain and fatigue and began forgetting to take her stomach pills.

Within a one month period, she noticed that the freckles on her face became lighter and her skin became smooth and silky. She was very happy because she did not have symptoms of fatigue syndrome malaise anymore, had good sleep, significantly decreased stomach pain and decreased menstrual cramps. Within a 4- month period, she noticed her hair was re-growing all over her head. Due to occupational use of paint thinner, she had lost hair on her forehead, which was now coming back. ​~International Journal of Cancer Research and Treatment (peer-reviewed journal)


An Australian male developed MS confirmed by lumbar puncture and magnetic resonance imaging (MRI) scan of the brain in 1989 at the age of 45. Thereafter, he was confined to a wheelchair for four years.

​In 1991, he was treated with pulse steroid therapy to manage symptoms, such as increasing weakness, sensory disturbance, numbness and tingling paresthesia. In 1999, a further episode occurred and then he again received pulse steroid therapy. In 2004, MRI scans showed extensive lesions in the brain and spinal cord, indicating secondary progressive MS. 

From February 2011, he again became wheelchair-bound and was no longer able to work.

​At the time, he presented with chronic urinary tract infection, urinary incontinence, severe muscle weakness, muscle pain, head fullness, tinnitus, poor memory, irritability and constipation.

From September 17, 2014, he received 0.5 ml GcMAF (1,500 ng/0.5 ml) intramuscularly or subcutaneously twice weekly. After three weeks of treatment with GcMAF, the following beneficial responses and changes were observed;


  • He slept through the night and got up at 7 am to use the bladder.

  • All medications for pain and urinary bladder control and antibiotics had been discontinued.

  • He had more energy and was able to drive an adapted car.

  • He went to work every day.

However, he still had some confusion.

By October 31, 2014, the responses to GcMAF treatment after six weeks were observed as follows;


  1. The patient was able to walk with assistance for the first time after four years of being wheelchair bound, although, as shown in Figure 1c, leg muscles were small and weak due to being confined to a wheelchair for four years. Moreover, he could also go up and down stairs.

  2. He had complete urinary bladder control without medication, even for bladder infections. 

  3. Brain fog was much better and he was animated and happy.

Subsequently, the patient was continuing treatment with second-generation GcMAF 0.5 ml, three times weekly and daily oral colostrum MAF." ~International Journal of Cancer Research and Treatment (peer-reviewed journal )​

  • Facebook
  • Twitter
  • YouTube

Skype Atlantis-Salud

+1 (321) 837 9262 USA (USA Canada)

24-hour office with a message service
+ 1  (1877) 891-1368 International

+593 993919977 on Signal & WhatsAPP

If you believe you have a medical emergency please see your physician immediately or dial 911.


© COPYRIGHT Atlantis Health ReTreat 2020 - 2021

FDA - TGA - EC-H International Disclaimer

The statements on this website have not been evaluated by the Food and Drug Administration USA (FDA) or Australian TGA or any other countries Department of health. By law, we must state these products are not intended to diagnose, treat, cure, or prevent any disease. 
The information on this site is provided for informational purposes only and should not be considered medical advice. 
Above Statement Required by Law.
All Rights Reserved and subject to our Terms and Conditions.